Download PDF
Horm Metab Res 2022; 54(11): 754-759
DOI: 10.1055/a-1891-6864
Original Article: Endocrine Research

LncRNA MAGI2-AS3 Inhibits Prostate Cancer Progression by Targeting the miR-142-3p

Renbao Hu 
1   Department of Urology, The Second People’s Hospital of Hefei, Hefei, China
,
Pei Wu
1   Department of Urology, The Second People’s Hospital of Hefei, Hefei, China
,
Jianhui Liu
1   Department of Urology, The Second People’s Hospital of Hefei, Hefei, China
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

Prostate cancer is a common male cancer with high morbidity and mortality worldwide. According to current research, the integration of long non-coding RNA (lncRNAs) and microRNA(miRNAs) can be expressed in a variety of cancers and play an important role in diagnosis. Based on this, this study explored the clinical role of lncRNA MAGI2-AS3 (MAGI2-AS3) in prostate cancer. By detecting the expression levels of MAGI2-AS3 and miR-142-3p, the correlation between the MAGI2-AS3 expression and the characteristics of clinical data was analyzed. ROC curve analysis was performed and the area under the ROC curve (AUC) was used to evaluate the diagnostic value of MAGI2-AS3 in distinguishing prostate cancer patients from healthy controls. The function of MAGI2-AS3 in prostate cancer cells was explored through CCK-8 and Transwell assays, and the relationship between MAGI2-AS3 and miR-142-3p was investigated by luciferase activity assay. MAGI2-AS3 has descended expression while miR-142-3p has an ascendant one in prostate cancer serum samples and cells. ROC curve analysis revealed that the AUC was 0.953 for MAGI2-AS3, with a sensitivity of 91.5% and specificity of 84.7%. Overexpression of MAGI2-AS3 in LNCaP and PC3 cells suppressed the biological function of the cell including proliferation capacity, migration level, and invasion. MAGI2-AS3 was considered a diagnostic biomarker for prostate cancer patients and inhibited prostate cancer progression by targeting miR-142-3p.

Key words

lncRNA MAGI2-AS3 - miR-142-3p - prostate cancer - diagnostic - migration - invasion


Publication History

Received: 18 May 2022

Accepted after revision: 22 June 2022

Article published online:
09 August 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Chen L, Hu W, Li G. et al. Inhibition of miR-9-5p suppresses prostate cancer progress by targeting StarD13. Cell Mol Biol Lett 2019; 24: 20
    CrossrefPubMedGoogle Scholar
  • 2 Kong Z, Wan X, Lu Y. et al. Circular RNA circFOXO3 promotes prostate cancer progression through sponging miR-29a-3p. J Cell Mol Med 2020; 24: 799-813
    CrossrefPubMedGoogle Scholar
  • 3 Wang D, Lu G, Shao Y. et al. MiR-182 promotes prostate cancer progression through activating Wnt/β-catenin signal pathway. Biomed Pharmacother 2018; 99: 334-339
    CrossrefPubMedGoogle Scholar
  • 4 Wang Y, Zhang Q, Guo B. et al. miR-1231 is downregulated in prostate cancer with prognostic and functional implications. Oncol Res Treat 2020; 43: 78-86
    CrossrefPubMedGoogle Scholar
  • 5 Lughezzani G, Sun M, Budäus L. et al. Effect of the number of biopsy cores on prostate cancer detection and staging. Fut Oncol (London, England) 2010; 6: 381-390
    CrossrefPubMedGoogle Scholar
  • 6 Chen Y, Li Z, Chen X. et al. Long non-coding RNAs: from disease code to drug role. Acta Pharm Sinica B 2021; 11: 340-354
    CrossrefPubMedGoogle Scholar
  • 7 Matsushita D, Arigami T, Okubo K. et al. The diagnostic and prognostic value of a liquid biopsy for esophageal cancer: a systematic review and meta-analysis. Cancers 2020; 12: 3070
    CrossrefPubMedGoogle Scholar
  • 8 Xu M, Yan Y, Zhu M. et al. Effects of long non-coding RNA Gm14461 on pain transmission in trigeminal neuralgia. J Inflam (London, England) 2020; 17: 1
    CrossrefPubMedGoogle Scholar
  • 9 Li CH, Chen Y. Targeting long non-coding RNAs in cancers: progress and prospects. Int J Biochem Cell Biol 2013; 45: 1895-1910
    CrossrefPubMedGoogle Scholar
  • 10 Lam MT, Li W, Rosenfeld MG. et al. Enhancer RNAs and regulated transcriptional programs. Trends Biochem Sci 2014; 39: 170-182
    CrossrefPubMedGoogle Scholar
  • 11 Fang Y, Fullwood MJ. Roles, Functions, and mechanisms of long non-coding RNAs in cancer. Genom Poteom Bioinform 2016; 14: 42-54
    CrossrefPubMedGoogle Scholar
  • 12 Zhou Z, Liu H, Wang C. et al. Long non-coding RNAs as novel expression signatures modulate DNA damage and repair in cadmium toxicology. Sci Rep 2015; 5: 15293
    CrossrefPubMedGoogle Scholar
  • 13 Wei GH, Wang X. lncRNA MEG3 inhibit proliferation and metastasis of gastric cancer via p53 signaling pathway. Eur Rev Med Pharmacol Sci 2017; 21: 3850-3856
    PubMedGoogle Scholar
  • 14 Cao HL, Liu ZJ, Huang PL. et al. lncRNA-RMRP promotes proliferation, migration and invasion of bladder cancer via miR-206. Eur Rev Med Pharmacol Sci 2019; 23: 1012-1021
    PubMedGoogle Scholar
  • 15 Bhan A, Soleimani M, Mandal SS. Long noncoding RNA and cancer: a new paradigm. Cancer Res 2017; 77: 3965-3981
    CrossrefPubMedGoogle Scholar
  • 16 Cai J, Chen Z, Chen X. et al. Coexpression network analysis identifies a novel nine-RNA signature to improve prognostic prediction for prostate cancer patients. BioMed Res Int 2020; 4264291
    PubMedGoogle Scholar
  • 17 Li D, Wang J, Zhang M. et al. LncRNA MAGI2-AS3 is regulated by BRD4 and promotes gastric cancer progression via maintaining ZEB1 overexpression by sponging miR-141/200a. Mol Ther Nucleic Acids 2020; 19: 109-123
    CrossrefPubMedGoogle Scholar
  • 18 Tang C, Cai Y, Jiang H. et al. LncRNA MAGI2-AS3 inhibits bladder cancer progression by targeting the miR-31-5p/TNS1 axis. Aging 2020; 12: 25547-25563
    CrossrefPubMedGoogle Scholar
  • 19 [Anonymous] Prostate cancer. Nursing Stand [Royal College of Nursing (Great Britain): 1987] 2016; 30: 17
    PubMedGoogle Scholar
  • 20 Xing C, Sun SG, Yue ZQ. et al. Role of lncRNA LUCAT1 in cancer. Biomed Pharmacother 2021; 134: 111158
    CrossrefPubMedGoogle Scholar
  • 21 Iyer MK, Niknafs YS, Malik R. et al. The landscape of long noncoding RNAs in the human transcriptome. Nat Genet 2015; 47: 199-208
    CrossrefPubMedGoogle Scholar
  • 22 Su W, Guo C, Wang L. et al. LncRNA MIR22HG abrogation inhibits proliferation and induces apoptosis in esophageal adenocarcinoma cells via activation of the STAT3/c-Myc/FAK signaling. Aging 2019; 11: 4587-4596
    CrossrefPubMedGoogle Scholar
  • 23 Sui Y, Chi W, Feng L. et al. LncRNA MAGI2-AS3 is downregulated in non-small cell lung cancer and may be a sponge of miR-25. BMC Pulm Med 2020; 20: 59
    CrossrefPubMedGoogle Scholar
  • 24 Kai-Xin L, Cheng C, Rui L. et al. Roles of lncRNA MAGI2-AS3 in human cancers. Biomed Pharmacother 2021; 141: 111812
    CrossrefPubMedGoogle Scholar
  • 25 Chang H, Zhang X, Li B. et al. MAGI2-AS3 suppresses MYC signaling to inhibit cell proliferation and migration in ovarian cancer through targeting miR-525-5p/MXD1 axis. Cancer Med 2020; 9: 6377-6386
    CrossrefPubMedGoogle Scholar
  • 26 Du S, Hu W, Zhao Y. et al. Long non-coding RNA MAGI2-AS3 inhibits breast cancer cell migration and invasion via sponging microRNA-374a. Cancer Biomark Sect A 2019; 24: 269-277
    CrossrefPubMedGoogle Scholar
  • 27 Xu T, He BS, Pan B. et al. MiR-142-3p functions as a tumor suppressor by targeting RAC1/PAK1 pathway in breast cancer. J Cell Physiol 2020; 235: 4928-4940
    CrossrefPubMedGoogle Scholar
  • 28 Tan YF, Chen ZY, Wang L. et al. MiR-142-3p functions as an oncogene in prostate cancer by targeting FOXO1. J Cancer 2020; 11: 1614-1624
    CrossrefPubMedGoogle Scholar
  • 29 Ren J, Li W, Pan G. et al. miR-142-3p modulates cell invasion and migration via PKM2-mediated aerobic glycolysis in colorectal cancer. Anal Cell Pathol (Amsterdam) 2021; 9927720
    PubMedGoogle Scholar
  • 30 Peng L, Sang H, Wei S. et al. circCUL2 regulates gastric cancer malignant transformation and cisplatin resistance by modulating autophagy activation via miR-142-3p/ROCK2. Mol Cancer 2020; 19: 156
    CrossrefPubMedGoogle Scholar
  • 31 Hua YQ, Zhu YD, Xie GQ. et al. Long non-coding SBF2-AS1 acting as a competing endogenous RNA to sponge microRNA-142-3p to participate in gemcitabine resistance in pancreatic cancer via upregulating TWF1. Aging 2019; 11: 8860-8878
    CrossrefPubMedGoogle Scholar